Aptamer Group, a developer of Optimer® binders used in drug discovery and diagnostics, reported £700,000 in revenue for the six months ending 31 December 2024—more than double the previous year’s £300,000. Its cash reserves increased to £2 million.
The company raised £2.6 million in August 2024 and reduced its fixed costs to £3 million annually. Recent milestones include human skin trials with Unilever for Optimer-based deodorant additives and successfully validating Alzheimer’s diagnostic binders. Lab-based tests with AstraZeneca have also shown promise in drug delivery for fibrosis treatments.
Commercially, Aptamer secured multiple contracts with leading pharmaceutical firms, many of them repeat customers. In December 2024, it extended a contract with a top 20 pharmaceutical company for protein purification applications. The firm’s fee-for-service pipeline supports major biotech and pharmaceutical development programmes.
